Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 182

1.

A giant exoplanet orbiting a very-low-mass star challenges planet formation models.

Morales JC, Mustill AJ, Ribas I, Davies MB, Reiners A, Bauer FF, Kossakowski D, Herrero E, Rodríguez E, López-González MJ, Rodríguez-López C, Béjar VJS, González-Cuesta L, Luque R, Pallé E, Perger M, Baroch D, Johansen A, Klahr H, Mordasini C, Anglada-Escudé G, Caballero JA, Cortés-Contreras M, Dreizler S, Lafarga M, Nagel E, Passegger VM, Reffert S, Rosich A, Schweitzer A, Tal-Or L, Trifonov T, Zechmeister M, Quirrenbach A, Amado PJ, Guenther EW, Hagen HJ, Henning T, Jeffers SV, Kaminski A, Kürster M, Montes D, Seifert W, Abellán FJ, Abril M, Aceituno J, Aceituno FJ, Alonso-Floriano FJ, Ammler-von Eiff M, Antona R, Arroyo-Torres B, Azzaro M, Barrado D, Becerril-Jarque S, Benítez D, Berdiñas ZM, Bergond G, Brinkmöller M, Del Burgo C, Burn R, Calvo-Ortega R, Cano J, Cárdenas MC, Guillén CC, Carro J, Casal E, Casanova V, Casasayas-Barris N, Chaturvedi P, Cifuentes C, Claret A, Colomé J, Czesla S, Díez-Alonso E, Dorda R, Emsenhuber A, Fernández M, Fernández-Martín A, Ferro IM, Fuhrmeister B, Galadí-Enríquez D, Cava IG, Vargas MLG, Garcia-Piquer A, Gesa L, González-Álvarez E, Hernández JIG, González-Peinado R, Guàrdia J, Guijarro A, de Guindos E, Hatzes AP, Hauschildt PH, Hedrosa RP, Hermelo I, Arabi RH, Otero FH, Hintz D, Holgado G, Huber A, Huke P, Johnson EN, de Juan E, Kehr M, Kemmer J, Kim M, Klüter J, Klutsch A, Labarga F, Labiche N, Lalitha S, Lampón M, Lara LM, Launhardt R, Lázaro FJ, Lizon JL, Llamas M, Lodieu N, López Del Fresno M, Salas JFL, López-Santiago J, Madinabeitia HM, Mall U, Mancini L, Mandel H, Marfil E, Molina JAM, Martín EL, Martín-Fernández P, Martín-Ruiz S, Martínez-Rodríguez H, Marvin CJ, Mirabet E, Moya A, Naranjo V, Nelson RP, Nortmann L, Nowak G, Ofir A, Pascual J, Pavlov A, Pedraz S, Medialdea DP, Pérez-Calpena A, Perryman MAC, Rabaza O, Ballesta AR, Rebolo R, Redondo P, Rix HW, Rodler F, Trinidad AR, Sabotta S, Sadegi S, Salz M, Sánchez-Blanco E, Carrasco MAS, Sánchez-López A, Sanz-Forcada J, Sarkis P, Sarmiento LF, Schäfer S, Schlecker M, Schmitt JHMM, Schöfer P, Solano E, Sota A, Stahl O, Stock S, Stuber T, Stürmer J, Suárez JC, Tabernero HM, Tulloch SM, Veredas G, Vico-Linares JI, Vilardell F, Wagner K, Winkler J, Wolthoff V, Yan F, Osorio MRZ.

Science. 2019 Sep 27;365(6460):1441-1445. doi: 10.1126/science.aax3198.

PMID:
31604272
2.

Kinetic analysis of the accumulation of a half-sandwich organo-osmium pro-drug in cancer cells.

Ballesta A, Billy F, Coverdale JPC, Song JI, Sanchez-Cano C, Romero-Canelón I, Sadler PJ.

Metallomics. 2019 Oct 16;11(10):1648-1656. doi: 10.1039/c9mt00173e.

PMID:
31528927
3.

Cessation of fluoxetine treatment increases alcohol seeking during relapse and dysregulates endocannabinoid and glutamatergic signaling in the central amygdala.

Suárez J, Khom S, Alén F, Natividad LA, Varodayan FP, Patel RR, Kirson D, Arco R, Ballesta A, Bajo M, Rubio L, Martin-Fardon R, Rodríguez de Fonseca F, Roberto M.

Addict Biol. 2019 Jul 24:e12813. doi: 10.1111/adb.12813. [Epub ahead of print]

PMID:
31339221
4.

Sex-, feeding-, and circadian time-dependency of P-glycoprotein expression and activity - implications for mechanistic pharmacokinetics modeling.

Okyar A, Kumar SA, Filipski E, Piccolo E, Ozturk N, Xandri-Monje H, Pala Z, Abraham K, Gomes ARGJ, Orman MN, Li XM, Dallmann R, Lévi F, Ballesta A.

Sci Rep. 2019 Jul 19;9(1):10505. doi: 10.1038/s41598-019-46977-0.

5.

Bupropion, a possible antidepressant without negative effects on alcohol relapse.

Ballesta A, Orio L, Arco R, Vargas A, Romero-Sanchiz P, Nogueira-Arjona R, de Heras RG, Antón M, Ramírez-López M, Serrano A, Pavón FJ, de Fonseca FR, Suárez J, Alen F.

Eur Neuropsychopharmacol. 2019 Jun;29(6):756-765. doi: 10.1016/j.euroneuro.2019.03.012. Epub 2019 May 4.

PMID:
31064683
6.

pH as a potential therapeutic target to improve temozolomide antitumor efficacy : A mechanistic modeling study.

Stéphanou A, Ballesta A.

Pharmacol Res Perspect. 2019 Jan 28;7(1):e00454. doi: 10.1002/prp2.454. eCollection 2019 Feb.

7.

Alcohol binge disrupts the rat intestinal barrier: the partial protective role of oleoylethanolamide.

Antón M, Rodríguez-González A, Ballesta A, González N, Del Pozo A, de Fonseca FR, Gómez-Lus ML, Leza JC, García-Bueno B, Caso JR, Orio L.

Br J Pharmacol. 2018 Dec;175(24):4464-4479. doi: 10.1111/bph.14501. Epub 2018 Oct 29.

8.

Circadian rest-activity rhythm as an objective biomarker of patient-reported outcomes in patients with advanced cancer.

Innominato PF, Komarzynski S, Palesh OG, Dallmann R, Bjarnason GA, Giacchetti S, Ulusakarya A, Bouchahda M, Haydar M, Ballesta A, Karaboué A, Wreglesworth NI, Spiegel D, Lévi FA.

Cancer Med. 2018 Sep;7(9):4396-4405. doi: 10.1002/cam4.1711. Epub 2018 Aug 7.

9.

Systems Biology, Systems Medicine, Systems Pharmacology: The What and The Why.

Stéphanou A, Fanchon E, Innominato PF, Ballesta A.

Acta Biotheor. 2018 Dec;66(4):345-365. doi: 10.1007/s10441-018-9330-2. Epub 2018 May 9. Review.

PMID:
29744615
10.

Increased plasma oleoylethanolamide and palmitoleoylethanolamide levels correlate with inflammatory changes in alcohol binge drinkers: the case of HMGB1 in women.

Antón M, Rodríguez-González A, Rodríguez-Rojo IC, Pastor A, Correas Á, Serrano A, Ballesta A, Alén F, Gómez de Heras R, de la Torre R, Rodríguez de Fonseca F, Orio L.

Addict Biol. 2018 Nov;23(6):1242-1250. doi: 10.1111/adb.12580. Epub 2017 Nov 27.

PMID:
29178411
11.

Systems Chronotherapeutics.

Ballesta A, Innominato PF, Dallmann R, Rand DA, Lévi FA.

Pharmacol Rev. 2017 Apr;69(2):161-199. doi: 10.1124/pr.116.013441. Review.

12.

In reply to the Letter to the Editor titled: "Comments on: Clinical implementation of a new electronic brachytherapy system for skin brachytherapy".

Pons-Llanas O, Ballester-Sánchez R, Celada-Álvarez FJ, Candela-Juan C, García-Martínez T, Llavador-Ros M, Botella-Estrada R, Barker CA, Ballesta A, Tormo-Micó A, Rodríguez S, Perez-Calatayud J.

J Contemp Brachytherapy. 2015 Aug;7(4):319-20. doi: 10.5114/jcb.2015.53991. Epub 2015 Sep 14. No abstract available.

13.

Identification of Circadian Determinants of Cancer Chronotherapy through In Vitro Chronopharmacology and Mathematical Modeling.

Dulong S, Ballesta A, Okyar A, Lévi F.

Mol Cancer Ther. 2015 Sep;14(9):2154-64. doi: 10.1158/1535-7163.MCT-15-0129. Epub 2015 Jul 3.

14.

Clinical implementation of a new electronic brachytherapy system for skin brachytherapy.

Pons-Llanas O, Ballester-Sánchez R, Celada-Álvarez FJ, Candela-Juan C, García-Martínez T, Llavador-Ros M, Botella-Estrada R, Barker CA, Ballesta A, Tormo-Micó A, Rodríguez S, Perez-Calatayud J.

J Contemp Brachytherapy. 2015 Jan;6(4):417-23. doi: 10.5114/jcb.2014.47996. Epub 2014 Dec 31. Review.

15.

Non-melanoma skin cancer treated with HDR Valencia applicator: clinical outcomes.

Tormo A, Celada F, Rodriguez S, Botella R, Ballesta A, Kasper M, Ouhib Z, Santos M, Perez-Calatayud J.

J Contemp Brachytherapy. 2014 Jun;6(2):167-72. doi: 10.5114/jcb.2014.43247. Epub 2014 Jun 3.

16.

Multiscale design of cell-type-specific pharmacokinetic/pharmacodynamic models for personalized medicine: application to temozolomide in brain tumors.

Ballesta A, Zhou Q, Zhang X, Lv H, Gallo JM.

CPT Pharmacometrics Syst Pharmacol. 2014 Apr 30;3:e112. doi: 10.1038/psp.2014.9.

17.

Diagnostic and predictive value of urine PCA3 gene expression for the clinical management of patients with altered prostatic specific antigen.

Rodón N, Trías I, Verdú M, Román R, Domínguez A, Calvo M, Banus JM, Ballesta AM, Maestro ML, Puig X.

Actas Urol Esp. 2014 Apr;38(3):150-5. doi: 10.1016/j.acuro.2013.07.009. Epub 2013 Oct 5. English, Spanish.

PMID:
24099827
18.

Cancer chronotherapeutics: experimental, theoretical, and clinical aspects.

Ortiz-Tudela E, Mteyrek A, Ballesta A, Innominato PF, Lévi F.

Handb Exp Pharmacol. 2013;(217):261-88. doi: 10.1007/978-3-642-25950-0_11. Review.

PMID:
23604483
19.

Data-driven modeling of SRC control on the mitochondrial pathway of apoptosis: implication for anticancer therapy optimization.

Ballesta A, Lopez J, Popgeorgiev N, Gonzalo P, Doumic M, Gillet G.

PLoS Comput Biol. 2013 Apr;9(4):e1003011. doi: 10.1371/journal.pcbi.1003011. Epub 2013 Apr 4.

20.
21.

Applying ecological and evolutionary theory to cancer: a long and winding road.

Thomas F, Fisher D, Fort P, Marie JP, Daoust S, Roche B, Grunau C, Cosseau C, Mitta G, Baghdiguian S, Rousset F, Lassus P, Assenat E, Grégoire D, Missé D, Lorz A, Billy F, Vainchenker W, Delhommeau F, Koscielny S, Itzykson R, Tang R, Fava F, Ballesta A, Lepoutre T, Krasinska L, Dulic V, Raynaud P, Blache P, Quittau-Prevostel C, Vignal E, Trauchessec H, Perthame B, Clairambault J, Volpert V, Solary E, Hibner U, Hochberg ME.

Evol Appl. 2013 Jan;6(1):1-10. doi: 10.1111/eva.12021. Epub 2012 Nov 16.

22.

An efficient kinetic model for assemblies of amyloid fibrils and its application to polyglutamine aggregation.

Prigent S, Ballesta A, Charles F, Lenuzza N, Gabriel P, Tine LM, Rezaei H, Doumic M.

PLoS One. 2012;7(11):e43273. doi: 10.1371/journal.pone.0043273. Epub 2012 Nov 13.

23.

A combined experimental and mathematical approach for molecular-based optimization of irinotecan circadian delivery.

Ballesta A, Dulong S, Abbara C, Cohen B, Okyar A, Clairambault J, Levi F.

PLoS Comput Biol. 2011 Sep;7(9):e1002143. doi: 10.1371/journal.pcbi.1002143. Epub 2011 Sep 8.

24.

Induction of apoptosis in HT-29 cells by extracts from isothiocyanates-rich varieties of Brassica oleracea.

Mas S, Crescenti A, Gassó P, Deulofeu R, Molina R, Ballesta A, Kensler TW, Lafuente A.

Nutr Cancer. 2007;58(1):107-14.

PMID:
17571973
25.

Lower specific micronutrient intake in colorectal cancer patients with tumors presenting promoter hypermethylation in p16(INK4a), p4(ARF) and hMLH1.

Mas S, Lafuente MJ, Crescenti A, Trias M, Ballesta A, Molina R, Zheng S, Wiencke JK, Lafuente A.

Anticancer Res. 2007 Mar-Apr;27(2):1151-6.

26.

[Can home prophylaxis for venous thromboembolism reduce mortality rates in patients with chronic obstructive pulmonary disease?].

Modesto-Alapont M, Nauffal-Manzur D, Ansótegui-Barrera E, Menéndez-Villanueva R, Ballesta A, Touza R, Perpiñá-Tordera M.

Arch Bronconeumol. 2006 Mar;42(3):130-4. Spanish.

27.

Induction of NAD(P)H quinone oxidoreductase by vegetables widely consumed in Catalonia, Spain.

Laso N, Mas S, Lafuente MJ, Llobet JM, Molina R, Ballesta A, Kensler TW, Lafuente A.

Nutr Cancer. 2005;52(1):49-58.

PMID:
16091004
28.

Simultaneous genotyping of CYP2C9*2, *3, and 5' flanking region (C-1189T) polymorphisms in a Spanish population through a new minisequencing multiplex single-base extension analysis.

Mas S, Crescenti A, Vidal-Taboada JM, Bergoñon S, Cuevillas F, Laso N, Molina R, Ballesta A, Lafuente A.

Eur J Clin Pharmacol. 2005 Oct;61(9):635-41. Epub 2005 Oct 19.

PMID:
16082538
29.

S-100beta and MIA in advanced melanoma in relation to prognostic factors.

Auge JM, Molina R, Filella X, Bosch E, Gonzalez Cao M, Puig S, Malvehy J, Castel T, Ballesta AM.

Anticancer Res. 2005 May-Jun;25(3A):1779-82.

30.

Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer.

Molina R, Auge JM, Filella X, Viñolas N, Alicarte J, Domingo JM, Ballesta AM.

Anticancer Res. 2005 May-Jun;25(3A):1773-8.

31.

Hypophosphatemic osteomalacia: a report of five cases and evaluation of bone markers.

Ros I, Alvarez L, Guañabens N, Peris P, Monegal A, Vázquez I, Cerdá D, Ballesta AM, Muñoz-Gómez J.

J Bone Miner Metab. 2005;23(3):266-9.

PMID:
15838631
32.

Complexed prostate-specific antigen for the detection of prostate cancer.

Filella X, Truan D, Alcover J, Gutierrez R, Molina R, Coca F, Ballesta AM.

Anticancer Res. 2004 Nov-Dec;24(6):4181-5.

33.

Decrease in specific micronutrient intake in colorectal cancer patients with tumors presenting Ki-ras mutation.

Laso N, Mas S, Jose Lafuente M, Casterad X, Trias M, Ballesta A, Molina R, Salas J, Ascaso C, Zheng S, Wiencke JK, Lafuente A.

Anticancer Res. 2004 May-Jun;24(3b):2011-20.

34.

Pro-gastrin-releasing peptide in patients with benign and malignant diseases.

Molina R, Auge JM, Alicarte J, Filella X, Viñolas N, Ballesta AM.

Tumour Biol. 2004 Jan-Apr;25(1-2):56-61.

PMID:
15192313
35.

Comparison of several combinations of free, complexed, and total PSA in the diagnosis of prostate cancer in patients with urologic symptoms.

Filella X, Truan D, Alcover J, Quintó L, Molina R, Luque P, Coca F, Ballesta AM.

Urology. 2004 Jun;63(6):1100-3; discussion 1103-4.

PMID:
15183958
36.

Effect of hemodialysis and renal failure on serum biochemical markers of bone turnover.

Alvarez L, Torregrosa JV, Peris P, Monegal A, Bedini JL, Martinez De Osaba MJ, Filella X, Martin G, Ricos C, Oppenheimer F, Ballesta AM.

J Bone Miner Metab. 2004;22(3):254-9.

PMID:
15108068
37.

Long-term biochemical response after bisphosphonate therapy in Paget's disease of bone. Proposed intervals for monitoring treatment.

Alvarez L, Peris P, Guañabens N, Vidal S, Quintó L, Monegal A, Pons F, Ballesta AM, Muñoz-Gómez J.

Rheumatology (Oxford). 2004 Jul;43(7):869-74. Epub 2004 Mar 30.

PMID:
15054158
38.

[Usefulness of PSA and its fractions in the diagnosis of prostate cancer].

Filella X, Truan D, Alcover J, Molina R, Luque P, Coca F, Ballesta AM.

Med Clin (Barc). 2004 Feb 28;122(7):241-4. Spanish.

PMID:
15012870
39.

Concentration of hydroxyproline in blood: a biological marker in occupational exposure to asbestos and its relationship with Pi*Z and Pi*S polymorphism in the alpha-1 antitrypsin gene.

Mas S, Casterad X, Laso N, Lafuente MJ, Panades R, Calleja A, Hernandez S, Turuguet D, Deulofeu R, Ballesta A, Ascaso C, Lafuente A.

Am J Ind Med. 2004 Feb;45(2):186-93.

PMID:
14748049
40.

Relationship of p53 with other oncogenes, cytokines and systemic lupus erythematosus activity.

Miret C, Molina R, Filella X, García-Carrasco M, Claver G, Ingelmo M, Ballesta A, Font J.

Tumour Biol. 2003 Aug-Sep;24(4):185-8.

PMID:
14654712
41.

Prospective evaluation of tumor markers (c-erbB-2 oncoprotein, CEA and CA 15.3) in patients with locoregional breast cancer.

Molina R, Filella X, Zanon G, Pahisa J, Alicarte J, Munoz M, Farrus B, Ballesta AM.

Anticancer Res. 2003 Mar-Apr;23(2A):1043-50.

PMID:
12820345
42.

Prospective evaluation of CEA and CA 15.3 in patients with locoregional breast cancer.

Molina R, Filella X, Alicarte J, Zanon G, Pahisa J, Munoz M, Farrus B, Ballesta AM.

Anticancer Res. 2003 Mar-Apr;23(2A):1035-41.

PMID:
12820344
43.

Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates.

Alvarez L, Peris P, Guañabens N, Vidal S, Ros I, Pons F, Filella X, Monegal A, Muñoz-Gomez J, Ballesta AM.

Arthritis Rheum. 2003 Mar;48(3):824-8.

44.

Cancer, genes, and catechol estrogen metabolites.

Mas S, Laso N, Lafuente MJ, Lafuente A, Molina R, Ballesta A, Zheng S, Wiencke JK.

Int J Clin Oncol. 2003 Feb;8(1):65-6. No abstract available.

PMID:
12601547
45.

Glutathione S-transferase (GSTM1 and GSTT1)-dependent risk for colorectal cancer.

Laso N, Lafuente MJ, Mas S, Trias M, Ascaso C, Molina R, Ballesta A, Rodriguez F, Lafuente A.

Anticancer Res. 2002 Nov-Dec;22(6A):3399-403.

PMID:
12530094
46.

[Dynamic ultrasonography in the diagnosis of gallbladder dysfunction: reliability of a simple method with easy clinical application].

Pons V, Ballesta A, Ponce M, Maroto N, Argüello L, Sopena R, Garrigues V, Ponce J.

Gastroenterol Hepatol. 2003 Jan;26(1):8-12. Spanish.

PMID:
12525321
47.

Pi*S and Pi*Z alpha 1 antitrypsin polymorphism and the risk for asbestosis in occupational exposure to asbestos.

Lafuente MJ, Casterad X, Laso N, Mas S, Panades R, Calleja A, Hernandez S, Turuguet D, Ballesta A, Ascaso C, Lafuente A.

Toxicol Lett. 2002 Nov 15;136(1):9-17.

PMID:
12368052
48.

BTA TRAK urine test increases the efficacy of cytology in the diagnosis of low-grade transitional cell carcinoma of the bladder.

Gibanel R, Ribal MJ, Filella X, Ballesta AM, Molina R, Alcaraz A, Alcover JB.

Anticancer Res. 2002 Mar-Apr;22(2B):1157-60.

PMID:
12168917
49.

S-100 protein serum levels in patients with benign and malignant diseases: false-positive results related to liver and renal function.

Molina R, Navarro J, Filella X, Castel T, Ballesta AM.

Tumour Biol. 2002 Jan-Feb;23(1):39-44.

PMID:
11893905
50.

Serum levels of beta2-microglobulin, neopterin, TNF-alpha and soluble receptors of TNF-alpha and interleukin-2 in intravenous drug abusers according to HIV-1 status and stage of the HIV-1 infection.

Bedini JL, García F, Miró JM, Aznar E, Serrano J, Lozano L, Mallolas J, Filella X, Vidal J, Latorre X, Gatell JM, Ballesta AM, Soriano E.

Clin Microbiol Infect. 1998 Jan;4(1):4-10.

Supplemental Content

Loading ...
Support Center